Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice.

ABSTRACT:

SUBMITTER: Wu S

PROVIDER: S-EPMC10978934 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice.

Wu Shuo S Yang Ping P Geng Zilong Z Li Yige Y Guo Zhizhao Z Lou Yingmei Y Zhang Shasha S Xiong Junhao J Hu Huan H Guo Xiaoling X Pu William T WT Zhang Yan Y Zhu Dan D Zhang Bing B

Cell research 20240209 4

PMID: 38337022

Similar Datasets

Base editing effectively prevents the early-onset hypertrophic cardiomyopathy in Mybpc3 mutant mice

Project description:Pathogenic variants in MYBPC3 (myosin-binding protein C3) are the leading cause of genetic hypertrophic cardiomyopathy (HCM). Currently, there is no specific and effective treatment for this disease. Base editing is an emerging modality for treating monogenic diseases; however, its effect on MYBPC3 cardiomyopathy remains unexplored. Mybpc3-R946X/R946X mice developed early-onset left ventricular hypertrophy, systolic dysfunction, ventricular dilatation, and arrythmias. SpRY-ABEmax inefficiently corrected the Mybpc3-R946X mutation. In contrast, SpRY-ABE8e increased the efficiency by 3.6-fold and retained low level off-target editing. In vivo administration of SpRY-ABE8e efficiently corrected Mybpc3-R946X mutation in cardiomyocytes and prevented heart function decline, hypertrophic cardiomyopathy, and ventricular dysfunction. The therapeutic efficacy of SpRY-ABE8e-mediated gene correction surmounted AAV-mediated Mybpc3 gene replacement.Our study unveiled the immense potential of base editing to treat fatal inherited cardiomyopathies and opened a new avenue for the therapeutic managements of inherited cardiac diseases.

2024-04-04 | GSE239872 | GEO

Base editing effectively prevents the early-onset hypertrophic cardiomyopathy in Mybpc3 mutant mice

Project description:Base editing effectively prevents the early-onset hypertrophic cardiomyopathy in Mybpc3 mutant mice

| PRJNA1001311 | ENA

Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.

Project description: Not available

| S-EPMC11194200 | biostudies-literature

Therapeutic base editing alleviates restrictive cardiomyopathy

Project description:Restrictive cardiomyopathy (RCM) is a severe cardiac disorder characterized by impaired ventricular filling and diastolic dysfunction, with mutations in sarcomeric proteins representing major causative factors. Mutations of TNNI3 gene (e.g. p.R192H) constitute major genetic causes of RCM, particularly affecting pediatric patients and being associated with poor prognosis. Here, we demonstrate that adenine base editor (ABE) is able effectively correct RCM-causing mutation and alleviate RCM in a murine model. We first developed a novel murine model harboring the Tnni3R193H mutation that recapitulates the hallmark features of human RCM. Importantly, targeted delivery of ABE via adeno-associated virus (AAV) achieved efficient and precise correction of the Tnni3R193H mutation in adult RCM mice, leading to significant improvement of cardiac functions. Our findings establish base editing as a therapeutic strategy for RCM and highlight its broader potential for treating genetic cardiomyopathies in clinical settings.

2025-04-30 | GSE295799 | GEO

Delayed onset of hypertrophic cardiomyopathy in a 61-year-old male patient with MYBPC3 mutation.

Project description: Not available

| S-EPMC11321234 | biostudies-literature

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice.

Project description: Not available

| S-EPMC9941048 | biostudies-literature

Therapeutic base editing alleviates restrictive cardiomyopathy

Project description:Therapeutic base editing alleviates restrictive cardiomyopathy

| PRJNA1256393 | ENA

Transcriptome analysis of patient derived induced pluripotent stem cell derived cardiomyocytes with severe, early onset hypertrophic cardiomyopathy due to biallelic MYBPC3 variants c.442G>A and c.506-1G>A

Project description:Induced pluripotent stem cells (iPSCs) were generated from a patient with severe, early onset hypertrophic cardiomyopathy due to pathogenic (c.506-1G>A) and low penetrance pathogenic (c.442G>A) variants in MYBPC3 in trans (i.e. MYBPC3 biallelic patient). Healthy control (WTC11, Coriell repository) iPSCs were used as reference. iPSCs were differentiated into cardiomyocytes for transcriptome analysis and assessment of the c.442G>A variant on MYBPC3 splicing.

2024-08-11 | GSE274124 | GEO

In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration.

Project description: Not available

| S-EPMC8983734 | biostudies-literature

Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.

Project description: Not available

| S-EPMC2563166 | biostudies-literature